Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.22
Mkt Cap
$139.057M
52W Low
$0.73
52W High
$2.6
52W Position info
67% above low
Off High info
53% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TLSA sits 67% above its 52-week low of $0.73.

Summary

Tiziana Life Sciences announced positive preclinical data for its lead candidate, nasal anti-CD3, showing its potential to reverse brain aging and improve cognition by reducing neuroinflammation.


Key Events · Product Development and Regulatory · TLSA

  • Positive Preclinical Data Announced

    Nasal anti-CD3 demonstrated potential to address neuroinflammation associated with aging, reverse key aspects of brain aging, and improve cognition in preclinical studies.

  • Mechanism of Action Reinforced

    Key study findings indicate nasal anti-CD3 dampens microglial activation and enhances neurogenesis in the hippocampus, supporting its role in modulating the immune system to reduce neuroinflammation.

  • Expanded Therapeutic Potential

    The data suggests potential applications for intranasal foralumab in age-related cognitive impairment, broadening its scope beyond ongoing clinical trials in other neurodegenerative indications.


Analysis · TLSA · Life Sciences

This filing announces positive preclinical data for Tiziana's lead candidate, nasal anti-CD3 (foralumab), demonstrating its potential to address neuroinflammation associated with aging and improve cognition. The data reinforces the drug's mechanism of action by showing it dampens microglial activation and enhances neurogenesis in the hippocampus. This expands the potential therapeutic applications for foralumab beyond its current neurodegenerative programs (MS, MSA, ALS, Alzheimer's), suggesting a new, large market opportunity in age-related cognitive impairment. While preclinical, these findings provide a positive signal for the drug's broad utility and could support future clinical development in this area.

At the time of this filing, TLSA was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $139.1M. The 52-week trading range was $0.73 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Jun 25, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.04 info
Change: -$0.080 (-7%) info
Market Cap: $124.101M info
TLSA
May 21, 2026, 11:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.04 info
Change: -$0.635 (-38%) info
Market Cap: $124.101M info
TLSA
May 19, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $1.04 info
Change: -$0.330 (-24%) info
Market Cap: $124.101M info
TLSA
May 14, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.04 info
Change: -$0.5101 (-33%) info
Market Cap: $124.101M info
TLSA
May 01, 2026, 5:00 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $1.34
Real-time Price: $1.04 info
Change: -$0.300 (-22%) info
Market Cap: $124.101M info